cDNA microarray and proteomic approaches in the study of brain diseases: Focus on schizophrenia and Alzheimer's disease

Pharmacology and Therapeutics

Volumn 100, Issue 1, 2003, Pages 63-74

  Marcotte, Eric R ^a   Srivastava, Lalit K ^a   Quirion, Rémi ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; cDNA microarray; Gene expression; Neuroscience; Proteomics; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE A1 RECEPTOR; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CREATINE KINASE; CYTOCHROME P450; DNA FRAGMENT; DOPAMINE RECEPTOR; GLUTAMATE AMMONIA LIGASE; GLUTAMIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; METABOTROPIC RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; N ETHYLMALEIMIDE; NEUROLEPTIC AGENT; NEUROPILIN; PRESENILIN 1; PRESENILIN 2; PROTEIN KINASE C BETA; PROTEIN TYROSINE PHOSPHATASE; REACTIVE OXYGEN METABOLITE; RNA; SEROTONIN RECEPTOR; SYNAPSIN II; SYNAPTOJANIN; SYNAPTOTAGMIN;

ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; BRAIN DISEASE; CEREBROSPINAL FLUID EXAMINATION; CHROMATOGRAPHY; CINGULATE GYRUS; CLONE; DENDRITIC SPINE; DNA MICROARRAY; DNA SEQUENCE; DOWN REGULATION; EXPRESSED SEQUENCE TAG; FINGER DERMATOGLYPHICS; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC LINKAGE; GENETIC TRANSCRIPTION; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HIPPOCAMPUS; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LOW DRUG DOSE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MAZE TEST; NERVE ENDING; NEUROTRANSMISSION; NONHUMAN; NORTHERN BLOTTING; NUCLEASE PROTECTION ASSAY; OXIDATION; PARIETAL LOBE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTHERN BLOTTING; TEMPORAL CORTEX; TWO DIMENSIONAL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

EID: 0141785242     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(03)00086-X     Document Type: Review

References (72)

1. Andreasen N.C. Schizophrenia: the fundamental questions. Brain Res Brain Res Rev. 31:2000;106-112.
2. Auld D.S., Kornecook T.J., Bastianetto S., Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol. 68:2002;209-245.
3. Banks R.E., Dunn M.J., Forbes M.A., Stanley A., Pappin D., Naven T., Gough M., Harnden P., Selby P.J. The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis - preliminary findings. Electrophoresis. 20:1999;689-700.
4. Banks R.E., Dunn M.J., Hochstrasser D.F., Sanchez J.C., Blackstock W., Pappin D.J., Selby P.J. Proteomics: new perspectives, new biomedical opportunities. Lancet. 356:2000;1749-1756.
5. Brazma A., Vilo J. Gene expression data analysis. FEBS Lett. 480:2000;17-24.
6. Brookes A.J. The essence of SNPs. Gene. 234:1999;177-186.
7. Byne W., Davis K.L. The role of prefrontal cortex in the dopaminergic dysregulation of schizophrenia. Biol Psychiatry. 45:1999;657-659.
8. Castegna A., Aksenov M., Aksenova M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R., Butterfield D.A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med. 33:2002;562-571.
9. Castegna A., Aksenov M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., Markesbery W.R., Butterfield D.A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem. 82:2002;1524-1532.
10. Choe L.H., Dutt M.J., Relkin N., Lee K.H. Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis. 23:2002;2247-2251.
11. Chowdari K.V., Mirnics K., Semwal P., Wood J., Lawrence E., Bhatia T., Deshpande S.N., Ferrell R.E., Middleton F.A., Devlin B., Levitt P., Lewis D.A., Nimgaonkar V.L. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet. 11:2002;1373-1380.
12. Colangelo V., Schurr J., Ball M.J., Pelaez R.P., Bazan N.G., Lukiw W.J. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res. 70:2002;462-473.
13. Colantuoni C., Purcell A.E., Bouton C.M., Pevsner J. High throughput analysis of gene expression in the human brain. J Neurosci Res. 59:2000;1-10.
14. Cowan W.M., Kopnisky K.L., Hyman S.E. The human genome project and its impact on psychiatry. Annu Rev Neurosci. 25:2002;1-50.
15. Davidsson P., Sjogren M., Andreasen N., Lindbjer M., Nilsson C.L., Westman-Brinkmalm A., Blennow K. Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Res Mol Brain Res. 109:2002;128-133.
16. Debouck C., Goodfellow P.N. DNA microarrays in drug discovery and development. Nat Genet. 21:1999;48-50.
17. DeLisi L.E. Critical overview of current approaches to genetic mechanisms in schizophrenia research. Brain Res Brain Res Rev. 31:2000;187-192.
18. Fend F., Emmert-Buck M.R., Chuaqui R., Cole K., Lee J., Liotta L.A., Raffeld M. Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis. Am J Pathol. 154:1999;61-66.
19. Garey L.J., Ong W.Y., Patel T.S., Kanani M., Davis A., Mortimer A.M., Barnes T.R., Hirsch S.R. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol Neurosurg Psychiatry. 65:1998;446-453.
20. Ginsberg S.D., Che S. RNA amplification in brain tissues. Neurochem Res. 27:2002;981-992.
21. Ginsberg S.D., Hemby S.E., Lee V.M., Eberwine J.H., Trojanowski J.Q. Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann Neurol. 48:2000;77-87.
22. Grant S.G., Blackstock W.P. Proteomics in neuroscience: from protein to network. J Neurosci. 21:2001;8315-8318.
23. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., Haroutunian V., Fienberg A.A. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA. 98:2001;4746-4751.
24. Holmes C. Genotype and phenotype in Alzheimer's disease. Br J Psychiatry. 180:2002;131-134.
25. Hu J.S., Durst M., Kerb R., Truong V., Ma J.T., Khurgin E., Balaban D., Gingeras T.R., Hoffman B.B. Analysis of drug pharmacology towards predicting drug behavior by expression profiling using high-density oligonucleotide arrays. Ann NY Acad Sci. 919:2000;9-15.
26. Husi H., Grant S.G. Proteomics of the nervous system. Trends Neurosci. 24:2001;259-266.
27. Ishii M., Hashimoto S., Tsutsumi S., Wada Y., Matsushima K., Kodama T., Aburatani H. Direct comparison of GeneChip and SAGE on the quantitative accuracy in transcript profiling analysis. Genomics. 68:2000;136-143.
28. Janus C., Westaway D. Transgenic mouse models of Alzheimer's disease. Physiol Behav. 73:2001;873-886.
29. Jope R.S., Song L., Grimes C.A., Pacheco M.A., Dilley G.E., Li X., Meltzer H.Y., Overholser J.C., Stockmeier C.A. Selective increases in phosphoinositide signaling activity and G protein levels in postmortem brain from subjects with schizophrenia or alcohol dependence. J Neurochem. 70:1998;763-771.
30. Kawanishi Y., Tachikawa H., Suzuki T. Pharmacogenomics and schizophrenia. Eur J Pharmacol. 410:2000;227-241.
31. Korolainen M.A., Goldsteins G., Alafuzoff I., Koistinaho J., Pirttila T. Proteomic analysis of protein oxidation in Alzheimer's disease brain. Electrophoresis. 23:2002;3428-3433.
32. Le Jeune H., Cecyre D., Rowe W., Meaney M.J., Quirion R. Ionotropic glutamate receptor subtypes in the aged memory-impaired and unimpaired Long-Evans rat. Neuroscience. 74:1996;349-363.
33. Liang P., Pardee A.B. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science. 257:1992;967-971.
34. Lipska B.K., Weinberger D.R. To model a psychiatric disorder in animals. Schizophrenia as a reality test. Neuropsychopharmacology. 23:2000;223-239.
35. Loring J.F., Wen X., Lee J.M., Seilhamer J., Somogyi R. A gene expression profile of Alzheimer's disease. DNA Cell Biol. 20:2001;683-695.
36. Luo L., Salunga R.C., Guo H., Bittner A., Joy K.C., Galindo J.E., Xiao H., Rogers K.E., Wan J.S., Jackson M.R., Erlander M.G. Gene expression profiles of laser-captured adjacent neuronal subtypes. Nat Med. 5:1999;117-122.
37. MacBeath G., Schreiber S.L. Printing proteins as microarrays for high-throughput function determination. Science. 289:2000;1760-1763.
38. Marcotte E.R., Pearson D.M., Srivastava L.K. Animal models of schizophrenia: a critical review. J Psychiatry Neurosci. 26:2000;395-410.
39. Marcotte E.R., Quirion R., Srivastava L.K. Gene expression changes in adult prefrontal cortex and nucleus accumbens following neonatal ventral hippocampal lesions. Soc Neurosci Abstr. 26:2000;385.14.
40. Marcotte E.R., Srivastava L.K., Quirion R. DNA microarrays in neuropsychopharmacology. Trends Pharmacol Sci. 22:2001;426-436.
41. Meaney M.J. Maternal care, gene expression, and the transmission of individual differences in stress reactivity across generations. Annu Rev Neurosci. 24:2001;1161-1192.
42. Middleton F.A., Mirnics K., Pierri J.N., Lewis D.A., Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci. 22:2002;2718-2729.
43. Mirnics K., Middleton F.A., Marquez A., Lewis D.A., Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron. 28:2000;53-67.
44. Mirnics K., Middleton F.A., Lewis D.A., Levitt P. Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci. 24:2001;479-486.
45. Mirnics K., Middleton F.A., Stanwood G.D., Lewis D.A., Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry. 6:2001;293-301.
46. Mufson E.J., Counts S.E., Ginsberg S.D. Gene expression profiles of cholinergic nucleus basalis neurons in Alzheimer's disease. Neurochem Res. 27:2002;1035-1048.
47. Nestler E.J. Common molecular and cellular substrates of addiction and memory. Neurobiol Learn Mem. 78:2002;637-647.
48. O'Donnell J., Diaz-Ruiz O., Godbout R., Quirion R. Hippocampal gene expression profiles in young, aged memory-impaired and aged memory-unimpaired Long Evans rats. Soc Neurosci Abstr. 2002;374.3.
49. O'Donnell J., Stemmelin J., Nitta A., Brouillette J., Quirion R. Gene expression profiling Following chronic NMDA receptor blockade-induced learning deficits in rats. Synapse. 2003;. in press.
50. Okada F., Crow T.J., Roberts G.W. G proteins (Gi, Go) in the medial temporal lobe in schizophrenia: preliminary report of a neurochemical correlate of structural change. J Neural Transm Gen Sect. 84:1991;147-153.
51. Pandey A., Mann M. Proteomics to study genes and genomes. Nature. 405:2000;837-846.
52. Pasinetti G.M. Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia. J Neurosci Res. 65:2001;471-476.
53. Pasinetti G.M., Ho L. From cDNA microarrays to high-throughput proteomics. Implications in the search for preventive initiatives to slow the clinical progression of Alzheimer's disease dementia. Restor Neurol Neurosci. 18:2001;137-142.
54. Poirier J. Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann NY Acad Sci. 924:2000;81-90.
55. Roses A.D. Pharmacogenetics and the practice of medicine. Nature. 405:2000;857-865.
56. Sagerstrom C.G., Sun B.I., Sive H.L. Subtractive cloning: past, present, and future. Annu Rev Biochem. 66:1997;751-783.
57. Sandberg R., Yasuda R., Pankratz D.G., Carter T.A., Del Rio J.A., Wodicka L., Mayford M., Lockhart D.J., Barlow C. Regional and strain-specific gene expression mapping in the adult mouse brain. Proc Natl Acad Sci U S A. 97:2000;11038-11043.
58. Schonberger S.J., Edgar P.F., Kydd R., Faull R.L., Cooper G.J. Proteomic analysis of the brain in Alzheimer's disease: molecular phenotype of a complex disease process. Proteomics. 1:2001;1519-1528.
59. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 47:2002;27-38.
60. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. J Comp Neurol. 392:1998;402-412.
61. Shaw C.A. Theoretical consideration of amplification strategies. Neurochem Res. 27:2002;1123-1131.
62. Shilling P.D., Kelsoe J.R. Functional genomics approaches to understanding brain disorders. Pharmacogenomics. 3:2002;31-45.
63. Sobell J.L., Mikesell M.J., McMurray C.T. Genetics and etiopathophysiology of schizophrenia. Mayo Clin Proc. 77:2002;1068-1082.
64. St George-Hyslop P.H. Genetic factors in the genesis of Alzheimer's disease. Ann NY Acad Sci. 924:2000;1-7.
65. Strizhkov B.N., Drobyshev A.L., Mikhailovich V.M., Mirzabekov A.D. PCR amplification on a microarray of gel-immobilized oligonucleotides: detection of bacterial toxin- and drug-resistant genes and their mutations. Biotechniques. 29:2000;844-854.
66. Tsuji T., Shimohama S. Analysis of the proteomic profiling of brain tissue in Alzheimer's disease. Dis Markers. 17:2001;247-257.
67. Tsuji T., Shiozaki A., Kohno R., Yoshizato K., Shimohama S. Proteomic profiling and neurodegeneration in Alzheimer's disease. Neurochem Res. 27:2002;1245-1253.
68. Vawter M.P., Crook J.M., Hyde T.M., Kleinman J.E., Weinberger D.R., Becker K.G., Freed W.J. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr Res. 58:2002;11-20.
69. Velculescu V.E., Zhang L., Vogelstein B., Kinzler K.W. Serial analysis of gene expression. Science. 270:1995;484-487.
70. Wells T., Carter D.A. Genetic engineering of neural function in transgenic rodents: towards a comprehensive strategy? J Neurosci Methods. 108:2001;111-130.
71. Yang C.Q., Kitamura N., Nishino N., Shirakawa O., Nakai H. Isotype-specific G protein abnormalities in the left superior temporal cortex and limbic structures of patients with chronic schizophrenia. Biol Psychiatry. 43:1998;12-19.
72. Yates J.R. III Mass spectrometry. From genomics to proteomics. Trends Genet. 16:2000;5-8.